Preparação e caracterização de um biocompósito obtido pela mistura de hidreto de titânio com nitrato de cálcio para implantes dentários

RESUMO Neste trabalho foram realizados estudos sobre a fabricação de um biocompósito à base de titânio para implantes dentários a partir da mistura de pó de hidreto de titânio (92%) com nitrato de cálcio (8% em volume). O pó de hidreto de titânio foi adicionado na solução aquosa de nitrato de cálcio, dissolvido por agitação mecânica, e em seguida os precursores foram misturados e dispersados/homogeneizados por ultrassom. Posteriormente, a mistura foi secada em evaporador rotativo, compactada com 600 MPa à temperatura ambiente, desmoldada e sinterizada em alto vácuo a 1200 oC durante 2 horas. Foi analisada a microestrutrura e fases formadas, as propriedades mecânicas, a rugosidade da superfície, a porosidade aberta, a molhabilidade da superfície e a citotoxicidade do biocompósito. As fases identificadas após a sinterização foram α-Ti e CaTiO3. O limite de resistência em compressão, o módulo de Young (E) e o ângulo de contato do biocompósito diminuíram significativamente com relação ao hidreto de titânio puro sinterizado nas mesmas condições. O limite médio de resistência em compressão do hidreto de titânio foi de 1794,67 MPa e do biocompósito foi de 481,36 MPa. O módulo de Young e o ângulo de contato do hidreto de titânio e do biocompósito foram de aproximadamente 112 GPa e 94 graus, e de 75 GPa e 83 graus, respectivamente. A rugosidade de superfície foi da mesma ordem de grandeza entre os materiais e ficou aproximadamente entre 1,4 e 1,5 µm (Ra) e 1,4 e 1,9 µm (Ra e Sa), medidas com rugosímetro de contato e com microscópio confocal a laser, respectivamente. A porosidade aberta do biocompósito sinterizado foi de aproximadamente três vezes maior do que aquela do hidreto de titânio sinterizado. Nos ensaios de citotoxicidade a porcentagem de células viáveis do biocompósito foi superior àquela do controle negativo e àquela do hidreto de titânio sinterizado

In Vivo Ectopic Implantation Model to Assess Human Mesenchymal Progenitor Cell Potential

Clinical interest on human mesenchymal progenitor cells (hMPC) relies on their potential applicability in cell-based therapies. An in vitro characterization is usually performed in order to define MPC potency. However, in vitro predictions not always correlate with in vivo results and thus there is no consensus in how to really assess cell potency. Our goal was to provide an in vivo testing method to define cell behavior before therapeutic usage, especially for bone tissue engineering applications. In this context, we wondered whether bone marrow stromal cells (hBMSC) would proceed in an osteogenic microenvironment. Based on previous approaches, we developed a fibrin/ceramic/BMP-2/hBMSCs compound. We implanted the compound during only 2 weeks in NOD-SCID mice, either orthotopically to assess its osteoinductive property or subcutaneously to analyze its adequacy as a cell potency testing method. Using fluorescent cell labeling and immunohistochemistry techniques, we could ascertain cell differentiation to bone, bone marrow, cartilage, adipocyte and fibrous tissue. We observed differences in cell potential among different batches of hBMSCs, which did not strictly correlate with in vitro analyses. Our data indicate that the method we have developed is reliable, rapid and reproducible to define cell potency, and may be useful for testing cells destined to bone tissue engineering purposes. Additionally, results obtained with hMPCs from other sources indicate that our method is suitable for testing any potentially implantable mesenchymal cell. Finally, we propose that this model could successfully be employed for bone marrow niche and bone tumor studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12015-013-9464-1) contains supplementary material, which is available to authorized users

A Review of Bioceramics and Fibrin Sealant

This review focuses on bone substitute composites made by mixing ceramic biomaterials with fibrin sealants. Different biomaterials such as coral, bone-derived materials, bioactive glass ceramics, and synthetic calcium phosphate have been mixed with fibrin sealant, resulting in a combination of the biological properties of the two components. This type of association has not produced identical results in all studies. In the past for some, the addition of fibrin sealant to the biomaterial failed to produce any significant, positive effect on osteointegration, whereas others found a positive impact on bone colonization. Despite the negative biological effects reported previously, bioceramic-fibrin composites have been widely used in various types of bone surgery because they are easy to manipulate. In particular, the intra-operative preparation of these composites makes it possible to add bone growth factors or autologous osteoprogenitor cells prior to bone reconstruction. The bone growth factors and autologous osteoprogenitor cells associated with the bioceramic-fibrin composites should provide surgeons with tissue engineered grafts with enhanced osteointegrative properties. This review discusses both the advantages and disadvantages, as well as the future perspectives, of using bioceramic-fibrin composites in various clinical indications